SCHEMBL1484751

SCHEMBL1484751

CC(NN)C(F)(F)F

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31112113 1.00
SCHEMBL25428292 1.00
Hydrochloric Acid SCHEMBL18988481 0.97
Hydrochloric Acid SCHEMBL25428369 0.97
Hydrochloric Acid SCHEMBL30214453 0.77
SCHEMBL23982512 0.75
SCHEMBL9431687 0.73
SCHEMBL529993 0.72 TDP1 (0.31)
SCHEMBL4792153 0.69
SCHEMBL7046050 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230322682-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE LOXO ONCOLOGY, INC. 2023-10-12 US claimed
EP-4683907-A1 SOLID STATE FORMS OF PIRTOBRUTINIB AND PROCESS FOR THE PREPARATION OF INTERMEDIATE THEREOF Dr. Reddy's Laboratories Limited (IN) 2026-01-28 EP disclosed
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO LTD (CN) 2025-04-10 US disclosed
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-10-29 US disclosed
EP-4448514-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF Lynk Pharmaceuticals Co. Ltd. (CN) 2024-10-23 EP disclosed
WO-2024194890-A1 SOLID STATE FORMS OF PIRTOBRUTINIB AND PROCESS FOR THE PREPARATION OF INTERMEDIATE THEREOF DR. REDDY’S LABORATORIES LIMITED (IN) 2024-09-26 WO disclosed
US-20240254118-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES, INC. 2024-08-01 US disclosed
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-04-18 US disclosed
US-20230322682-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE LOXO ONCOLOGY, INC. 2023-10-12 US disclosed
US-20230322682-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE LOXO ONCOLOGY, INC. 2023-10-12 US disclosed
WO-2011036284-A1 BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2011-03-31 WO disclosed
US-20110076291-A1 BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2011-03-31 US disclosed
US-6013836-A PARTICULARLY ACTIVE AGAINST MOTHS AND BEETLES AND THEIR INSECT GROWTH REGULATING ACTIVITY WITHOUT ADVERSE IMPACT ON BENEFICIAL INSECTS; CROPS; FORESTRY ROHM AND HAAS COMPANY (US) 2000-01-11 US disclosed
US-5424333-A Anthelmintic N'-substituted-N,N'-disubstitutedhydrazines ROHM AND HAAS COMPANY (US) 1995-06-13 US disclosed
EP-0361645-B1 ORGANIC HYDRAZINE DERIVATIVES FOR PHARMACEUTICAL USE ROHM AND HAAS COMPANY (US) 1993-09-29 EP disclosed
US-5117057-A Insecticidal N' substituted-N-N'-disubstituted-hydrazines ROHM AND HAAS COMPANY (US) 1992-05-26 US disclosed
EP-0286746-B1 INSECTICIDAL N-(OPTIONALLY SUBSTITUTED) - N'-SUBSTITUTED-N,N'-DISUBSTITUTED- HYDRAZINES ROHM AND HAAS COMPANY (US) 1991-02-27 EP disclosed
EP-0361645-A2 Organic hydrazine derivatives for pharmaceutical use ROHM AND HAAS COMPANY (US) 1990-04-04 EP disclosed
EP-0286746-A1 Insecticidal N-(optionally substituted) - N'-substituted-N,N'-disubstituted- hydrazines ROHM AND HAAS COMPANY (US) 1988-10-19 EP disclosed
US-4328223-A 2-Amino-3a,4,5,6-tetrahydro-perimidine derivatives and their medicinal use in combatting circulatory diseases BAYER AKTIENGESELLSCHAFT (DE) 1982-05-04 US disclosed